Low-flow, low-gradient aortic stenosis with reduced ejection fraction and a borderline dobutamine study
A 77-year-old retired teacher has progressive exertional dyspnoea for 6 months, now limiting on walking 100 metres, with one episode of exertional syncope. He has hypertension, type 2 diabetes and chronic kidney disease stage 3b (eGFR 38), and a previous CABG 12 years ago with a patent LIMA-LAD. Echocardiography: LVEF 32%, LV end-diastolic volume 130 mL, aortic valve area 0.85 cm² by continuity, mean gradient 26 mmHg, peak velocity 3.0 m/s, dimensionless index 0.21, moderate LV hypertrophy, no other valve disease, LV stroke volume index 28 mL/m². Dobutamine stress echocardiography increases stroke volume by 22% and peak velocity to 3.4 m/s, with mean gradient rising to 38 mmHg and calculated valve area 0.88 cm². CT shows severe porcelain calcification of the ascending aorta. He is independent, cognitively intact, and walks without aids but has a Clinical Frailty Scale score of 3.
1. How do you interpret the echocardiographic and dobutamine data, and does this patient have severe aortic stenosis?
Read the worked answer
This is low-flow, low-gradient AS with reduced LVEF, a classic diagnostic trap. The resting numbers (AVA 0.85 cm² - severe by area; mean gradient 26 mmHg - not severe by gradient) are discordant because the low stroke volume index (28 mL/m²) means the gradient underestimates severity.
Dobutamine stress echocardiography is used to resolve the discordance:
- Flow reserve is present: stroke volume rose by 22%, above the usual 20% threshold.
- True severe AS is suggested when the mean gradient rises above ~40 mmHg while the valve area remains ≤1.0 cm². Here the gradient reached 38 mmHg (near threshold) and the area essentially did not change (0.85 → 0.88 cm²).
- Pseudo-severe AS would show the area increasing above 1.0–1.2 cm² with the gradient staying modest. That did not happen.
- The dimensionless index of 0.21 and the calcification burden also support significant disease.
Conclusion: highly likely true severe AS with reduced LVEF, a class I indication for valve replacement once symptomatic - and he is symptomatic with exertional syncope, which is an ominous sign. The dobutamine result should be interpreted quantitatively (projected AVA) and by the multidisciplinary heart team, not by gradient alone.
2. What intervention would you recommend, and how do the porcelain aorta and frailty influence that decision?
Read the worked answer
He has a class I indication for aortic valve replacement: symptomatic severe AS with reduced LVEF. The question is the mode.
TAVI is the preferred option here:
- Age 77 with a hostile ascending aorta (porcelain) makes surgical cross-clamping and cannulation high risk for stroke and aortic injury; conventional SAVR may require circulatory arrest with aortic replacement.
- Reduced LVEF with low flow increases surgical risk, and TAVI is at least non-inferior to SAVR in intermediate/high-risk patients.
- A previous patent LIMA-LAD means redo sternotomy is not needed for the aortic procedure, and significant CAD is already revascularised.
- Frailty score 3 with independence suggests he can benefit; extreme frailty would argue for palliation instead.
Practical points:
- Heart team discussion is mandatory, with CT sizing of the annulus and iliofemoral access, and assessment of coronary height and the risk of coronary obstruction.
- Cerebral embolic protection and careful catheter manipulation reduce stroke risk in porcelain aorta.
- Manage the CKD (hydration, avoid nephrotoxins, contrast minimisation), and optimise diabetes control.
- If the dobutamine study had shown no contractile reserve, the outlook is worse and the benefit of AVR is more limited; a trial of inotropic support and a frank discussion of goals would be needed. Even then, "no reserve" is no longer an absolute contraindication, but the heart team should weigh likely futility.
3. He asks what happens if he declines intervention. How would you counsel him, and what medical therapy would you use?
Read the worked answer
Counsel honestly and specifically, because the natural history of symptomatic severe AS is poor. Once symptoms appear, average survival without intervention is around 2–3 years, and his exertional syncope is a particularly high-risk feature. Declining surgery is a legitimate choice, but he should make it with accurate information about the alternatives and about what palliative care can and cannot do.
Medical therapy (no therapy alters the valve disease itself):
- Treat hypertension cautiously - avoid aggressive afterload reduction that can cause hypotension in severe AS; ACE inhibitors are not forbidden but must be titrated with monitoring.
- Diuretics for congestion, in the lowest effective dose, with monitoring of renal function and blood pressure.
- Statin and diabetes therapy for vascular risk.
- Treat anaemia and iron deficiency, which worsen symptoms.
- Consider supervised exercise/rehabilitation and advance care planning.
- Avoid nitrates and vasodilators for the syncope and avoid vigorous Valsalva.
Reassess: the door should remain open - many patients who initially decline later accept TAVI. Arrange early review, involve the heart team and palliative care in parallel, document the discussion, and address his fear of the procedure explicitly (local anaesthesia/sedation for transfemoral TAVI, short hospital stay, and the stroke and pacemaker risks).